New study tests HIV drug safety in newborns
NCT ID NCT07275606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the HIV drug cabotegravir is safe for newborns who were exposed to HIV during birth. About 44 healthy babies will receive the drug either by mouth or injection. The goal is to find the right dose and check for side effects, helping to protect these infants from HIV infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGParow Valley, 7505, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Long-acting HIV shot studied in patients with severe kidney problems
- Can two hours of mindfulness ease chronic pain in HIV patients?
- Can a clinic-and-social-media campaign boost HIV prevention among black women?
- Choice of Long-Acting HIV prevention could transform care for young people in rural south africa